newsfilter
← Latest News
GlobeNewswire·

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

MNPR
  • Monopar Therapeutics presented baseline data from the Phase 3 FoCus trial for ALXN1840 (tiomolibdate choline) at the AASLD Liver Meeting 2026 in Denver.
  • Dr. Frederick K. Askari reported that hepatic, neurologic, & psychiatric disease burdens were common in both treatment-experienced & treatment-naïve patients.
  • Cirrhosis was found in 39% of treatment-experienced patients & 30% of treatment-naïve patients at baseline.
  • Neurologic symptoms were present in 79% of treatment-experienced patients & 83% of treatment-naïve patients.
  • Psychiatric symptoms were observed in 75% of treatment-experienced patients & 70% of treatment-naïve patients.
  • 73% of evaluable patients had at least two of the following conditions: cirrhosis, neurologic symptoms, or psychiatric symptoms.
  • 47% of treatment-experienced patients were not within guideline-recommended copper target ranges at baseline.
  • 31% of patients on standard-of-care therapy for over 12 months had 24-hour urinary copper excretion above recommended targets.
  • Professor Aftab Ala presented data showing neutral molybdenum balance & no molybdenum toxicity in subjects treated with ALXN1840.
  • Serum uric acid levels remained within normal limits for subjects treated with ALXN1840 for six years.
  • ALXN1840 is a first-in-class albumin tripartite complex activator designed to mobilize & sequester excess copper in Wilson disease patients.
  • The Phase 3 pivotal trial met its primary endpoint by demonstrating rapid & sustained copper mobilization greater than standard of care over 48 weeks.
  • Monopar Therapeutics also develops radiopharmaceutical programs including MNPR-101-Zr, MNPR-101-Lu, & MNPR-101-Ac for advanced cancers.